Monday, August 09, 2021 6:25:40 PM
Good point on NP matters…” what we should care about are results and actions”.
Action: File HIV BLA years after promised.
Results: RTF and still delayed resubmission as HIV put on Back burner by CEO.
Action: CD10 Trial M2M CoVID.
Results: Failure to meet endpoints.
Action: CD 12 Trial S2C CoVID
Results: Failure to meet endpoints.
Action: 2X CEO and BOD unjustly awarded themselves shares of CYDY ( stealing).
Results: Reversal by agreement and rebuke ofMGT. by Delaware Magistrates
Action: Egomaniacal lawsuit against Pestell
Results: Finding of no cause of dismissal for Pestell and award of damages and fees of $7.6 million.
Action: CEO Touts anecdotal information and “ mined trial data”
Results: FDA so pissed off it issues a public rebuke of the claims regarding LL and CYDY’s ( and hence NPs] lack of skill/ proficiency in designing trial protocols.
Action: Promises “ revenue in Philippines next week”
Results: Nada.. crickets… no revenue.
How does this guy still have a job. Actions and results are clear and documented to show abject failure of management.
The only question is…
Can one man accidentally fail on this scale or is something nefarious going on? Oh, I left out the SEC and DOJ investigations noted in the 10- K, as well as NPs 2 felonies and personal bankruptcies.
Action: File HIV BLA years after promised.
Results: RTF and still delayed resubmission as HIV put on Back burner by CEO.
Action: CD10 Trial M2M CoVID.
Results: Failure to meet endpoints.
Action: CD 12 Trial S2C CoVID
Results: Failure to meet endpoints.
Action: 2X CEO and BOD unjustly awarded themselves shares of CYDY ( stealing).
Results: Reversal by agreement and rebuke ofMGT. by Delaware Magistrates
Action: Egomaniacal lawsuit against Pestell
Results: Finding of no cause of dismissal for Pestell and award of damages and fees of $7.6 million.
Action: CEO Touts anecdotal information and “ mined trial data”
Results: FDA so pissed off it issues a public rebuke of the claims regarding LL and CYDY’s ( and hence NPs] lack of skill/ proficiency in designing trial protocols.
Action: Promises “ revenue in Philippines next week”
Results: Nada.. crickets… no revenue.
How does this guy still have a job. Actions and results are clear and documented to show abject failure of management.
The only question is…
Can one man accidentally fail on this scale or is something nefarious going on? Oh, I left out the SEC and DOJ investigations noted in the 10- K, as well as NPs 2 felonies and personal bankruptcies.
3X
God Bless America!
Recent CYDY News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
